Advertisement

The Body: The Complete HIV/AIDS Resource
Sign up for free e-mail updates!The Body en Espanol
DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>
San Francisco AIDS Foundation
La Combinación Doble: Aceptación y Polémica

8 de Julio 2001

Extracto de bibliografía

  1. Bangsberg, D.R. and others. Adherence to HAART predicts progression to AIDS. 8th Conference on Retroviruses and Opportunistic Infections. Chicago. February 4-8, 2001. Poster 483.Bernstein, B. and others. Absence of resistance to Kaletra (ABT-378/r) observed through 48 weeks of therapy in antiretroviral-naive subjects. 8th CROI. Poster 453.

  2. Brun, S. and others. Patterns of protease inhibitor cross-resistance in viral isolates with reduced susceptibility to ABT-378. 8th CROI. Poster 452.

  3. Burger, D. and others. Both short-term virological efficacy and drug-associated nephrotoxicity are related to indinavir (IDV) pharmacokinetics (PK) in HIV-1-infected Thai patients. 8th CROI. Poster 730.

  4. Burger, D. and others. Indinavir pharmacokinetics are related to efficacy and toxicity. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection. Lisbon. October 23-27, 1999. Poster 826.

  5. Cadman, J. The great salvage therapy drug juggle. GMHC Treatment Issues 12(4): 1-6. April 1998.

  6. Cameron, D.W. and others. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13(2): 213-224. February 4, 1999.

  7. Cameron, D.W. and others. Three-year follow-up and conditional outcomes survival analysis of ritonavir (RTV) plus saquinavir (SQV) therapy in HIV infection. 7th CROI. San Francisco. January 30-February 2, 2000. Poster 533.

  8. Chaillou, S. and others. Does ritonavir "baby" dose induce specific mutations in salvage combination therapy? A VIRADAPT sub-study. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto. September 17-20, 2000. Poster 1267.Condra, J.H. and others. Resistance to HIV-1 protease inhibitors and predicted responses to therapy. 3rd International Workshop on Salvage Therapy for HIV Infection. Chicago. April 12-14, 2000. Oral presentation 2.

  9. Danner, S. Breaking new ground: the future of HIV therapy; redefining the art of HIV management. 5th International Congress on Drug Therapy in HIV Infection (satellite symposium). Glasgow, Scotland. October 23, 2000. Lecture 6.

  10. Degen, O. and others. Amprenavir (APV) and ritonavir (RTV): intraindividual comparison of different doses and influence of concomitant NNRTI on steady-state pharmacokinetics in HIV-infected patients. 8th CROI. Poster 739.


Índice
Antes | Proximo


This article was provided by San Francisco AIDS Foundation.


Advertisement